Bone resorption markers. Preliminary longitudinal study.

PELLEGRINI GG; GONZALES CHAVES MMS; SOMOZA J; FRIEDMAN SM; ZENI SN

Montreal, Quebec, Canada

Congreso; 30 th Annual Meeting of the American Society for Bone and Mineral Research; 2008

ASBMR

Previously, we measured terminal C-telopeptide of collagen type I (CTX) in saliva. The present longitudinal experimental study sought to determine whether salivary concentrations of CTX have the same response as in serum samples under different conditions: normal, increased, and reduced bone remodeling. Thirty rats were ovariectomized (OVX) and 10 rats were sham operated. The rats were divided into 4 groups (G) and treated as follows for 45 days: G1 = SHAM+vehicle; G2 = OVX + 8 mg olpadronate (OPD)/100 g body weight (BW); G3 = OVX + 4 mg OPD/100 g BW ;G4 = OVX + vehicle. Saliva and serum CTX (ng/ml) were determined by ELISA (Rat Laps. Osteometer BioTech, Denmark) at baseline (t=0), at t=10, t=20 and t=45 days of experience. Results: (table 1) In both samples, there were not differences in CTX levels at baseline. G4 presented the highest CTX levels compared to the other 3 groups throughout the experience (P <0.05). After treatment, the saliva and serum CTX values remained unchanged in G1 and G2 and decreased in G3 (P <0.01). Levels were similar in G1 and G2 and significantly lower in G3 (p<0.05). Conclusions: Saliva determinations detect increase and decrease in bone remodeling. BASE LINE T= 10ds T= 20ds T= 45ds saliva Serum saliva Serum saliva Serum saliva serum G1 mean 3,40 39,3 3,93 34,9 3,10 34,4 3,10 33,3 SD 0,95 3,1 1,70 11,3 0,82 3,2 1,17 7,4 G2 mean 3,31 30,1 3,59 42,5 3,17 38,8 3,21 37,6 SD 0,96 9,5 0,88 2,2 1,13 5,7 1,19 8,5 G3 3,56 38,7 3,44 31,8 2,80 33,4 2,77 24,1 0,16 OPD 0,73 2,4 0,59 5,3 0,40 7,8 0,66 7,9 G4 mean 3,30 34,9 4,40